{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:08:40Z","timestamp":1747282120391,"version":"3.40.5"},"reference-count":0,"publisher":"Sociedad Espanola de Quimioterapia","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Quimioter"],"published-print":{"date-parts":[[2025,5,14]]},"abstract":"<jats:p>Human infections by Bordetella bronchiseptica are increasing in recent years. However, due to the lack of clinical susceptibility\/resistance breakpoints, antimicrobial treatment is complex. Business Intelligence (BI) is a tool that allows to record and analyze large amounts of data in a very short time. The aim of this study was to analyze a cohort of patients with B. bronchiseptica infections focusing on how BI can help guide empirical antimicrobial therapy Demographic, clinical, and microbiological data about B. bronchiseptica infections were recovered. Then, MIC50\/90 of several antibiotics was automatically calculated through the BI. Thirteen B. bronchiseptica infections were identified. The lowest MICs90 were for carbapenem, aminoglycoside, fluoroquinolones, and tetracyclines. The EUCAST PK-PD (non-species related) breakpoints showed that only piperacillin\/tazobactam, imipenem and meropenem would be appropriate treatments to use empirically. In conclusion, BI systems have great potential to optimize the empirical antibiotic treatment in these types of infections.<\/jats:p>","DOI":"10.37201\/req\/125.2024","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T16:19:42Z","timestamp":1741882782000},"page":"208-213","source":"Crossref","is-referenced-by-count":0,"title":["Usefulness of business intelligence to guide antimicrobial treatment decision in infections by infrequent microorganism such as Bordetella bronchiseptica"],"prefix":"10.37201","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6373-9724","authenticated-orcid":false,"given":"\u00c1ngel","family":"Rodr\u00edguez-Villodres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Valentina","family":"Hoffmann-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-4600","authenticated-orcid":false,"given":"Pedro","family":"Camacho-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3635-4930","authenticated-orcid":false,"given":"Jos\u00e9 Antonio","family":"Lepe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"23328","published-online":{"date-parts":[[2025,3,13]]},"container-title":["Revista Espa\u00f1ola de Quimioterapia"],"original-title":["Utilidad de los sistemas de an\u00e1lisis de datos para guiar la decisi\u00f3n de tratamiento antimicrobiano en infecciones por microorganismos poco frecuentes como Bordetella bronchiseptica"],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:24:09Z","timestamp":1747211049000},"score":1,"resource":{"primary":{"URL":"https:\/\/revespquimioterapia.com\/articulo\/usefulness-of-business-intelligence-to-guide-antimicrobial-treatment-decision-in-infections-by-infrequent-microorganism-such-as-bordetella-bronchiseptica"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":0,"issue-title":["Volume 38, Issue 3"],"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,14]]},"published-print":{"date-parts":[[2025,5,14]]}},"URL":"https:\/\/doi.org\/10.37201\/req\/125.2024","relation":{},"ISSN":["1988-9518","0214-3429"],"issn-type":[{"type":"electronic","value":"1988-9518"},{"type":"print","value":"0214-3429"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}